Who we are
About Legal Ipamorelin
A research briefing on the ipamorelin record — read through the body-composition lens, with the regulatory status laid out straight.
What this site is
Legal Ipamorelin is a research briefing on the peer-reviewed literature about ipamorelin, written in plain English. It is a reading of the studies, not a service: it treats no one, employs no clinicians, hands out no medical advice, and makes or sells nothing. Think of it as a briefing on a body of research, organized around the body-composition questions people most often ask, and written in a forward-looking but honest voice. Every figure we cite traces back to a study you can open and check yourself.
What "legal" means in our name
The word "legal" in this site's name is editorial framing — a lens, not a service. It signals that we take the regulatory and legal status of ipamorelin seriously and report it accurately, not that we offer legal advice or sell a "legal" product. Nothing here is legal counsel. We summarize the public regulatory record — approval status, compounding-pharmacy actions, anti-doping classification — so a reader can do informed due diligence. The position we occupy is that of a careful reader of the literature and the regulatory filings, nothing more.
Is ipamorelin fda approved?
No. Ipamorelin is not FDA-approved as a drug for any indication. It was investigated — most notably for postoperative ileus (the failed Phase 2 trial NCT00672074) — but never approved [3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list (following nominator withdrawal in September 2024) and reviewed ipamorelin acetate and free base at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting; it is not an approved bulk substance for compounding. It is marketed only as a research chemical, and it is prohibited in sport at all times under the World Anti-Doping Agency's category S2. We report this status; we do not endorse or recommend any use.
How we work
Our content is built from a curated, citation-audited research corpus on ipamorelin. We lead each page with a plain-English summary, keep the full technical depth below it, and attach a bracketed citation to every quantitative claim. We separate three kinds of statement carefully: established study findings (cited), community-reported effects (clearly labeled anecdotal), and regulatory facts (sourced to the public record). We never publish a human dosing recommendation, an efficacy promise, or a purchase pathway. When the evidence is thin or negative — as much of the human ipamorelin evidence is — we say so plainly rather than dressing it up.